Positive preliminary data from Protalix's taliglucerase alfa switchover trial for Gaucher disease

Links shared publicly online about this topic.

757
total visits

Positive preliminary data from Protalix's taliglucerase alfa switchover trial for Gaucher disease

Protalix BioTherapeutics, Inc., announced today positive preliminary data from the first 15 patients that completed the Company's nine month, worldwide, multi-center, open-label, switchover trial of taliglucerase alfa for the treatment of Gaucher disease under a protocol cleared by the U.S. Food and Drug Administration (FDA). The data indicate that patients can safely be switched to taliglucerase alfa from imiglucerase (Cerezyme®).

View full resource at news-medical.net

Tags: Lipid Storage Disease, Gaucher Disease, Disease and Condition, Diet and Nutrition, Drug, FDA, disease